Julie Byrne

Characterisation of the HLA-DRB1*07:01 biomarker for lapatinib-induced liver toxicity during treatment of early-stage breast cancer patients with lapatinib in combination with trastuzumab and/or taxanes

M. Piccart, Z. Aziz, D. Fraser, 2017, The Pharmacogenomics Journal.